Partner Clyde Tinnen was quoted in a Reorg article, “Healthcare Mergers Dwindle Despite Increase in Sector Activity,” about an expected decline in industry deals for both health care providers and pharmaceutical companies in light of the coronavirus pandemic.
Tinnen said enforcement changes made by regulators so far in response to the spread of the coronavirus appear aimed at collaboration and conduct rather than M&A. For industry players contemplating uncertain territories, he said, “the agencies will be there to guide them on how much information can be shared without divulging prohibited competitive information such as pricing data.”
(Subscription required.)
People
Related News
August 19, 2025
In the News
Gustavo Resendiz Featured in Q&A on Secondary Market Momentum – 'Investors want liquidity'
Foley & Lardner LLP partner Gustavo Resendiz is featured in the Crunchbase News Q&A, "Why Secondary Funds Still Can’t Keep Up With Investor Demand," lending insight into the accelerating investor momentum towards secondary transactions.
August 18, 2025
In the News
David Simon Coauthors Piece on Empowering Lawyers as Strategic Business Partners
Foley & Lardner LLP partner David Simon coauthored The Agenda article, "Turn Your Corporate Lawyer into a Strategic Weapon," published by Financial Times.
August 15, 2025
In the News
Gregory Husisian on Voluntary Disclosures to Customs – 'Importing has never been riskier'
Foley & Lardner LLP partner Gregory Husisian authored the SupplyChainBrain article, "Best Practices for Making Voluntary Disclosures to Customs," sharing insight on this vital strategy for companies looking to mitigate risk from U.S. Customs and Border Protection.